InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,537.02
(
0.51%
)
US TECH 100
19,641.60
(
0.83%
)
Dow Jones
39,308.00
(
-0.06%
)
Brent Oil
87.33
(
0.48%
)
Bitcoin
58,354.89
(
-3.00%
)
Post# of 252484
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119978
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 131487

Saturday, 11/19/2011 4:11:46 PM

Saturday, November 19, 2011 4:11:46 PM

Post# of 252484

…after reading [the NEJM paper on Xarelto] I didn't pay attention to the 'median of 4.7 days after the acute incident'. I think you're right that it is very unlikely that in this setting Xarelto will impact on Lovenox in ACS. That doesn't change my view on Xarelto results in ACS #msg-68991909.

Thanks, Idit. I value your opinion highly, so it’s good to know that we’re on the same wavelength. Regards, Dew

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up